Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is app...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Ernesto, Maiorano, Brigida Anna, Pagliara, Monica Maria, Sammarco, Maria Grazia, Dosa, Tommaso, Martini, Maurizio, Rindi, Guido, Bria, Emilio, Blasi, Maria Antonietta, Tortora, Giampaolo, Schinzari, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460374/
https://www.ncbi.nlm.nih.gov/pubmed/31024839
http://dx.doi.org/10.3389/fonc.2019.00232
Descripción
Sumario:Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.

Ejemplares similares